Revance Announces Closing of Public Offering of Common Stock
Gross Proceeds of Offering Total 115.0 Million
The securities described above were offered by Revance pursuant to an
automatic shelf registration statement previously filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Revance is a clinical-stage biotechnology company focused on the development, manufacturing, and commercialization of novel neuromodulators for multiple aesthetic and therapeutic indications. Revance is leveraging its proprietary portfolio of botulinum toxin type A compounds, formulated with its patented and proprietary peptide excipient technology, to address unmet needs in large and growing neuromodulator markets.
"Revance Therapeutics" and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.:
Jeanie Herbert, 714-325-3584
Burns McClellan, Inc.:
John Grimaldi, 212-213-0006
Mariann Caprino, 917-242-1087
Nadine Tosk, 504-453-8344